Liu, Jielu
Nie, Mu
Dong, Caijuan
Säfholm, Jesper
Pejler, Gunnar
Nilsson, Gunnar
Adner, Mikael
Article History
Received: 8 August 2022
Accepted: 1 November 2022
First Online: 7 November 2022
Competing interests
: Dr. Pejler and Adner report that the concept of using monensin as an anti-mast cell agent is currently under patenting. All the other authors declare that there is no conflict of interest.